SANERGY GROUP (02459) plans to discount approximately 17.82% to allocate up to 228 million shares, raising approximately HK$18.4 million net.
Shengneng Group (02459) announced that on January 25, 2026, the company entered into a placing agreement with the placing agent. Under the terms and conditions of the placing agreement, the placing agent (as the company's placing agent) agrees to use its best efforts to solicit not less than 6 placees (who and their ultimate beneficial owners must be independent third parties) to subscribe for the placing shares.
SANERGY GROUP (02459) announced that on January 25, 2026, the company entered into a placing agreement with the placing agent. Under the terms and conditions of the placing agreement, the placing agent (acting as the company's placing agent) agrees to use its best efforts to procure not less than 6 placees (who and their ultimate beneficial owners must be independent third parties) to subscribe for the placing shares.
Assuming that there are no changes in the issued share capital of the company from the date of this announcement to the completion of the placing, the maximum number of placing shares under the placing is 228 million shares, representing approximately 13.33% of the total issued shares of the company as of the date of this announcement; and approximately 11.76% of the total issued shares of the company after the placing shares have been allotted and issued (assuming full subscription for the placing shares and no changes in the total issued shares of the company other than the issuing and allotment of the placing shares.
The total nominal value of the placing shares will be $2.28 million. The placing price of $0.083 per placing share represents a discount of approximately 17.82% to the closing price of $0.101 per share on the Stock Exchange of Hong Kong on January 23, 2026 (the last trading day before the placing agreement date).
Assuming full subscription for the placing shares, the total proceeds from the placing are expected to be approximately $18.9 million, with the net proceeds (after deducting all relevant expenses, costs, and fees to be incurred or borne by the company) expected to be approximately $18.4 million. The estimated net price per placing share of the company is approximately $0.081.
Related Articles

ASCLETIS-B (01672) announced that the first batch of subjects in the 13-week Phase II study of the oral small molecule GLP-1R agonist ASC30 for the treatment of diabetes has been dosed in the United States.

On January 23, BEKE-W (02423) spent 3 million US dollars to repurchase 492,000 shares.

Revenue exceeds expectations with a 30% growth, profit validation of "AI + chronic disease service" mode. What did this company, which does not compete for traffic, do right?
ASCLETIS-B (01672) announced that the first batch of subjects in the 13-week Phase II study of the oral small molecule GLP-1R agonist ASC30 for the treatment of diabetes has been dosed in the United States.

On January 23, BEKE-W (02423) spent 3 million US dollars to repurchase 492,000 shares.

Revenue exceeds expectations with a 30% growth, profit validation of "AI + chronic disease service" mode. What did this company, which does not compete for traffic, do right?

RECOMMEND

Paul Chan Says Hong Kong Has Licensed 11 Virtual Asset Exchanges, Stablecoin Licenses Expected Later This Year
22/01/2026

Ministry Of Finance And Other Departments Introduce Comprehensive Fiscal And Financial Policies To Boost Domestic Demand
22/01/2026

Capital Migration: Five Years On, An In‑Depth Analysis Of China’s 11 High‑Growth Venture Capital Tracks In 2025
22/01/2026


